Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting

Journal of Clinical Lipidology

Volumn 7, Issue 5, 2013, Pages 399-407

  Simpson, Ross J ^a   Tunceli, Kaan ^b   Ramey, Dena R ^b   Neff, David R ^b   Kern, David M ^c   Hsieh, Hui Min ^c   Wertz, Debra A ^c   Stephenson, Judith J ^c   Marrett, Elizabeth ^b   Tomassini, Joanne E ^b   Jacobson, Terry A ^d  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HEALTHCORE INC   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Goal attainment; High risk; LDL C; Managed care; Monotherapy; Statins; Treatment changes

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT EDUCATION; PRIORITY JOURNAL; TREATMENT DURATION;

GOAL ATTAINMENT; HIGH-RISK; LDL-C; MANAGED CARE; MONOTHERAPY; STATINS; TREATMENT CHANGES;

COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RISK; TIME FACTORS;

EID: 84885018175     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.06.002     Document Type: Article

References (30)

1. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. A.L. Catapano, Z. Reiner, and G. De Backer ESC/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
3. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
4. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
5. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
6. J.M. Foody, S.G. Sajjan, and X.H. Hu Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients J Clin Lipidol 4 2010 126 132
7. G.A. Nichols, S. Nag, and W. Chan Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update Am Heart J 154 2007 554 560
8. H.D. Aronow, G. Hess, J. Hill, A. Kuznik, and L.Z. Liu Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol Am J Ther 17 2010 167 175
9. D. Atar, R. Carmena, and P. Clemmensen Clinical review. Impact of statin substitution policies on patient outcomes Ann Med 41 2009 242 256
10. R.H. Kon, M.W. Russo, B. Ory, P. Mendys, and R.J. Simpson Jr. Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising J Clin Lipidol 2 2008 51 57
11. D.A. Rublee, and J.P. Burke LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice Postgrad Med 122 2010 16 24
12. V.J. Willey, M.F. Bullano, N.N. Shoetan, and S.K. Gandhi Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin Curr Med Res Opin 26 2010 121 128
13. M. Bermingham, J. Hayden, and I. Dawkins Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care Clin Ther 33 2011 1180 1189
14. Crestor (rosuvastatin calcium) tablets [package insert] 2012 AstraZeneca Wilmington, DE
15. Pravachol [package insert] 2011 Bristol-Meyers Squibb Princeton, NJ
16. Zocor (simvastatin) tablets [package insert] 2010 Merck & Co, Inc Whitehouse Station, NJ
17. Mevacor [product insert] 2010 Merck & Co, Inc Whitehouse Station, NJ
18. LESCOL/LESCOL XL (fluvastatin) [package insert] 2011 Novartis East Hanover, NJ
19. Lipitor (atorvastatin calcium) tablets [package insert] 2012 Pfizer New York, NY
20. P.P. Toth, C.M. Ballantyne, and M.H. Davidson Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction J Clin Lipidol 6 2012 180 191
21. R. Butler, and J. Wainwright Cholesterol lowering in patients with CHD and metabolic syndrome [letter] Lancet 369 2007 27
22. F. Colivicchi, M. Tubaro, and M. Santini Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes Int J Cardiol 152 2011 56 60
23. B. Phillips, C. Roberts, A.E. Rudolph, S. Morant, F. Aziz, and C. O'Regan Switching statins: the impact on patient outcomes Br J Cardiol 14 2007 280 285
24. K. Tunceli, S.G. Sajjan, and D.R. Ramey Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients J Clin Lipidol 4 2010 491 500
25. A. Helin-Salmivaara, P.T. Lavikainen, and M.J. Korhonen Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study Am J Manag Care 16 2010 116 122
26. D.M. Mann, M. Woodward, P. Muntner, L. Falzon, and I. Kronish Predictors of nonadherence to statins: a systematic review and meta-analysis Ann Pharmacother 44 2010 1410 1421
27. D.A. Rublee, S.Y. Chen, J. Mardekian, N. Wu, P. Rao, and L. Boulanger Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy Am J Ther 19 2012 24 32
28. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
29. R.J. Simpson Jr., J. Signorovitch, and H. Birnbaum Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population Mayo Clin Proc 84 2009 1065 1072
30. R.J. Simpson Jr., and P. Mendys The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review J Clin Lipidol 4 2010 462 471